Education
About Us
Working with TipRanks
Follow Us
Sprint Bioscience AB (DE:5JA1)
FRANKFURT:5JA1
Total Valuation
Sprint Bioscience AB has a market cap or net worth of €21.14M. The enterprise value is €107.54M.
Market Cap€21.14M
Enterprise Value€107.54M
Share Statistics
Sprint Bioscience AB has 105,515,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,515,540
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sprint Bioscience AB’s return on equity (ROE) is 0.77 and return on invested capital (ROIC) is 81.67%.
Return on Equity (ROE)0.77
Return on Assets (ROA)0.67
Return on Invested Capital (ROIC)81.67%
Return on Capital Employed (ROCE)0.82
Revenue Per Employee4.40M
Profits Per Employee2.41M
Employee Count38
Asset Turnover1.22
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sprint Bioscience AB is 2.2. Sprint Bioscience AB’s PEG ratio is -0.00309.
PE Ratio2.2
PS Ratio0.81
PB Ratio1.14
Price to Fair Value1.14
Price to FCF1.63
Price to Operating Cash Flow2.77
PEG Ratio-0.00309
Income Statement
In the last 12 months, Sprint Bioscience AB had revenue of 167.17M and earned 91.74M in profits. Earnings per share was 0.99.
Revenue167.17M
Gross Profit97.33M
Operating Income97.33M
Pretax Income91.74M
Net Income91.74M
EBITDA98.40M
Earnings Per Share (EPS)0.99
Cash Flow
In the last 12 months, operating cash flow was 84.25M and capital expenditures -94.00K, giving a free cash flow of 84.16M billion.
Operating Cash Flow84.25M
Free Cash Flow84.16M
Free Cash Flow per Share0.80
Dividends & Yields
Sprint Bioscience AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.62
52-Week Price Change84.00%
50-Day Moving Average0.13
200-Day Moving Average0.06
Relative Strength Index (RSI)64.03
Average Volume (3m)83.00
Important Dates
Sprint Bioscience AB upcoming earnings date is May 13, 2026, TBA (Confirmed).
Last Earnings DateFeb 11, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Sprint Bioscience AB as a current ratio of 7.60, with Debt / Equity ratio of 0.00%
Current Ratio7.60
Quick Ratio7.60
Debt to Market Cap0.00
Net Debt to EBITDA-1.29
Interest Coverage Ratio15.68
Taxes
In the past 12 months, Sprint Bioscience AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Sprint Bioscience AB EV to EBITDA ratio is 0.10, with an EV/FCF ratio of 0.11.
EV to Sales0.06
EV to EBITDA0.10
EV to Free Cash Flow0.11
EV to Operating Cash Flow0.11
Balance Sheet
Sprint Bioscience AB has €126.70M in cash and marketable securities with €0.00 in debt, giving a net cash position of €126.70M billion.
Cash & Marketable Securities€126.70M
Total Debt€0.00
Net Cash€126.70M
Net Cash Per Share€1.20
Tangible Book Value Per Share€1.29
Margins
Gross margin is 75.95%, with operating margin of 58.22%, and net profit margin of 54.88%.
Gross Margin75.95%
Operating Margin58.22%
Pretax Margin54.88%
Net Profit Margin54.88%
EBITDA Margin58.86%
EBIT Margin58.22%
Analyst Forecast
The average price target for Sprint Bioscience AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―